Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease

NCT07141810 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Fibrotic Interstitial Lung Disease

Interventions

DRUG: Antifibrotic drugs (nidanib or pirfenidone)

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China